Skip to main content
. 2023 Jun 3;13(8):1802–1813. doi: 10.1158/2159-8290.CD-23-0153

Figure 1.

Figure 1. Efficacy of brigimadlin in patients with advanced/metastatic solid tumors in phase Ia. Best change in size of target lesion from baseline in all patients enrolled to phase Ia.

Efficacy of brigimadlin in patients with advanced/metastatic solid tumors in phase Ia. Best change in size of target lesion from baseline in all patients enrolled to phase Ia.